<SEC-DOCUMENT>0001193125-19-240440.txt : 20190909
<SEC-HEADER>0001193125-19-240440.hdr.sgml : 20190909
<ACCEPTANCE-DATETIME>20190909064610
ACCESSION NUMBER:		0001193125-19-240440
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20190909
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190909
DATE AS OF CHANGE:		20190909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACADIA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001070494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				061376651
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50768
		FILM NUMBER:		191080803

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-558-2871

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d800506d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:acad="http://www.acadia-pharm.com/20190909" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2019-09-09_to_2019-09-09">ACADIA PHARMACEUTICALS INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2019-09-09_to_2019-09-09">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2019-09-09_to_2019-09-09">0001070494</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="acad-20190909.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2019-09-09_to_2019-09-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001070494</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-09-09</xbrli:startDate> <xbrli:endDate>2019-09-09</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="font-size:10pt;width:8.5in;margin:0 auto"> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <p style="margin-bottom:0px;margin-top:4pt"></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">UNITED STATES</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">SECURITIES AND EXCHANGE COMMISSION</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">WASHINGTON, D.C. 20549</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:10pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0px;margin-top:10pt">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2019-09-09_to_2019-09-09">8-K</ix:nonNumeric> </span></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:10pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:10pt">CURRENT REPORT</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Pursuant to Section&#160;13 or 15(d)</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">of the Securities Exchange Act of 1934</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:10pt">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2019-09-09_to_2019-09-09" format="ixt:datemonthdayyearen">September&#160;9, 2019</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:10pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:24pt;margin-bottom:0px;margin-top:10pt"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">ACADIA Pharmaceuticals Inc.</span> </p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">(Exact name of registrant as specified in its charter)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:10pt;margin-bottom:0px">&#160;</p></div>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:10pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2019-09-09_to_2019-09-09" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2019-09-09_to_2019-09-09">000-50768</ix:nonNumeric> </span></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2019-09-09_to_2019-09-09">06-1376651</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(State or other jurisdiction of</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">incorporation or organization)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Commission</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">File Number)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(IRS Employer</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Identification No.)</p></td></tr>
<tr style="font-size:1pt;">
<td colspan="3" style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2019-09-09_to_2019-09-09">3611 Valley Centre Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2019-09-09_to_2019-09-09">Suite 300</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2019-09-09_to_2019-09-09">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2019-09-09_to_2019-09-09" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td>&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2019-09-09_to_2019-09-09">92130</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Address of principal executive offices)</p></td>
<td>&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Zip Code)</p></td></tr></table> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:10pt">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2019-09-09_to_2019-09-09">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2019-09-09_to_2019-09-09">558-2871</ix:nonNumeric> </span></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:10pt">N/A</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Former name or former address, if changed since last report.)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:10pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:10pt">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form <span style="white-space:nowrap">8-K): </span></p> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2019-09-09_to_2019-09-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2019-09-09_to_2019-09-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12) </span></td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2019-09-09_to_2019-09-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"> <span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b)) </span></td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2019-09-09_to_2019-09-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"> <span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c)) </span></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:10pt">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:10pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Title of each class</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Trading</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Symbol(s)</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Name of each exchange</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">on which registered</p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2019-09-09_to_2019-09-09">Common Stock, par value $0.0001 per share</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2019-09-09_to_2019-09-09">ACAD</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2019-09-09_to_2019-09-09" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:10pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#32;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167;&#32;<span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="font-family:Times New Roman;margin-left:0%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:10pt">Emerging growth company&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2019-09-09_to_2019-09-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal">&#9744;</span></p> <p style="margin-bottom:0px;margin-top:10pt"></p> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <div></div> <p style="margin-top:0"></p></div>

<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;8.01 </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Other Events.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">On September 9, 2019, the Company announced that its Phase 3 HARMONY study, a double-blind, placebo-controlled relapse prevention study of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis, met its primary endpoint, demonstrating a highly statistically significant longer time to relapse of psychosis with pimavanserin compared to placebo in a planned interim efficacy analysis. Upon the recommendation of the study&#8217;s independent data monitoring committee, which met to review the data from the planned interim efficacy analysis, the study will now be stopped early based on pre-specified stopping criteria requiring a one-sided p-value less than 0.0033 on the study&#8217;s primary endpoint.</p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Company is planning to meet with the FDA regarding a supplemental NDA submission in 2020 and the results from the HARMONY study will be submitted for presentation at upcoming medical meetings.</p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The HARMONY study included a 12-week open-label stabilization period during which patients with dementia-related psychosis were treated with pimavanserin 34 mg once daily. Dose reduction to 20 mg once daily was allowed if clinically justified within the first four weeks. Following the 12-week stabilization period, patients who met pre-specified criteria for treatment response were then randomized into the double-blind period of the study to continue their pimavanserin dose (34 mg or 20 mg per day) or switched to placebo and followed for up to 26 weeks or until a relapse of psychosis occurred. The primary endpoint in the study was time to relapse in the double-blind period. Relapse (significant worsening of dementia-related psychosis after prior stabilization) was defined in the study by one or more of the following: hospitalization due to dementia-related psychosis, significant deterioration of dementia-related symptoms on clinical scales, withdrawal from the study due to lack of efficacy, or the use of an off-label antipsychotic medication for the treatment of dementia-related delusions and/or hallucinations. All potential relapses and discontinuations in the double-blind portion of the study were adjudicated by an independent adjudication committee to determine if protocol defined relapse criteria were met.</p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">A copy of ACADIA&#8217;s press release issued September 9, 2019 is furnished herewith as Exhibit 99.1.</p> <p style="font-family:Times New Roman;font-style:italic;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:18pt">Forward-Looking Statements</p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">Statements in this Current Report that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to: intended activities with respect to the HARMONY study following the interim analysis, expected timelines with respect to full data from the HARMONY study and the Company&#8217;s planned engagement with the FDA. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2018 as well as its subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.</p> <div></div> <p style="margin-top:0"></p>
 </div>



<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;9.01 </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Financial Statements and Exhibits.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">(d) <span style="text-decoration:underline">Exhibits</span>. </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td></td>
<td></td>
<td></td>
<td style="width:3%;"></td>
<td style="width:94%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">99.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d800506dex991.htm">Press release dated September&#160;9, 2019 </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">104 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Cover Page Interactive Data File (embedded within the Inline XBRL document) </p> </td> </tr> </table> <div></div> <p style="margin-top:0"></p>
 </div>



<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">SIGNATURES </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:0px;margin-right:auto">
<tr>
<td style="width:45%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td style="width:1%;"></td>
<td style="width:44%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;text-indent:2.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Date: September&#160;9, 2019 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">ACADIA Pharmaceuticals Inc. </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">By: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;margin-bottom:1pt;font-size:10pt;margin-top:0pt;border-bottom:1px solid #000000">/s/ Austin D. Kim </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Name: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Austin D. Kim </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Title: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Executive Vice President, General Counsel&#160;&#038; Secretary </p> </td> </tr> </table> <div></div> <p style="margin-top:0"></p>
 </div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d800506dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g800506g0909073947301.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as
Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>- Pimavanserin achieved robust statistical
superiority over placebo in time to relapse of dementia-related psychosis at planned interim efficacy analysis </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>- Pimavanserin has
the potential to be the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug for the treatment of dementia-related psychosis </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>- Approximately 1.2&nbsp;million patients in the United States are diagnosed with dementia-related psychosis </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>- Conference call and webcast to be held today at 8:30 a.m. Eastern Time </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>SAN DIEGO </B>&#150; <B>September</B><B></B><B>&nbsp;9, 2019</B> &#150; ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that its
Phase 3 HARMONY study, a double-blind, placebo-controlled relapse prevention trial evaluating pimavanserin for the treatment of dementia-related psychosis, met its primary endpoint, demonstrating a highly statistically significant longer time to
relapse of psychosis with pimavanserin compared to placebo in a planned interim efficacy analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Upon the recommendation of the
study&#146;s independent data monitoring committee, which met to review the data from the planned interim efficacy analysis, the study will now be stopped early based on <FONT STYLE="white-space:nowrap">pre-specified</FONT> stopping criteria
requiring a <FONT STYLE="white-space:nowrap">one-sided</FONT> <FONT STYLE="white-space:nowrap">p-value</FONT> less than 0.0033 on the study&#146;s primary endpoint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Company is planning to meet with the FDA regarding a supplemental NDA submission in 2020 and the results from the HARMONY study will be
submitted for presentation at upcoming medical meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The FDA previously granted Breakthrough Therapy Designation for pimavanserin for
the treatment of dementia-related psychosis. No drug is approved by the FDA for the treatment of dementia-related psychosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;Psychosis adds dramatically to the marked burden that dementia patients already carry and is one of the most <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">challenging-to-manage</FONT></FONT> aspects of the disease for caregivers,&#148; said Jeffrey Cummings, M.D., Sc.D., Director Emeritus of Cleveland Clinic Lou Ruvo Center for Brain Health
in Las Vegas. &#147;With no approved treatment options available today for dementia-related psychosis, the pimavanserin study results represent a meaningful advance that will potentially bring us a much
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
needed therapy for this debilitating disease.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;We are very excited that
today&#146;s results bring us one step closer to the potential of offering patients with dementia-related psychosis a critically needed treatment option,&#148; said Serge Stankovic, M.D., M.S.P.H., ACADIA&#146;s President. &#147;We look forward to
speaking with the FDA about a supplemental new drug application to support pimavanserin for the treatment of dementia-related psychosis. I want to thank all of the patients, their families, and the investigators for their participation in this
important study.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>About the HARMONY Study </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">HARMONY is a Phase 3 study designed to evaluate the efficacy and safety of pimavanserin for the treatment of delusions and hallucinations
associated with dementia-related psychosis across a broad population of patients with the most common subtypes of dementia including: Alzheimer&#146;s disease, dementia with Lewy bodies, Parkinson&#146;s disease dementia, vascular dementia, and
frontotemporal dementia spectrum disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The HARMONY study included a <FONT STYLE="white-space:nowrap">12-week</FONT> open-label
stabilization period during which patients with dementia-related psychosis were treated with pimavanserin 34 mg once daily. Dose reduction to 20 mg once daily was allowed if clinically justified within the first four weeks. Following the <FONT
STYLE="white-space:nowrap">12-week</FONT> stabilization period, patients who met <FONT STYLE="white-space:nowrap">pre-specified</FONT> criteria for treatment response were then randomized into the double-blind period of the study to continue their
pimavanserin dose (34 mg or 20 mg per day) or switched to placebo and followed for up to 26 weeks or until a relapse of psychosis occurred. The primary endpoint in the study was time to relapse in the double-blind period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Relapse (significant worsening of dementia-related psychosis after prior stabilization) was defined in the study by one or more of the
following: hospitalization due to dementia-related psychosis, significant deterioration of dementia-related symptoms on clinical scales, withdrawal from the study due to lack of efficacy, or the use of an
<FONT STYLE="white-space:nowrap">off-label</FONT> antipsychotic medication for the treatment of dementia-related delusions and/or hallucinations. All potential relapses and discontinuations in the double-blind portion of the study were adjudicated
by an independent adjudication committee to determine if protocol defined relapse criteria were met.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>Conference Call and Webcast
Information </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">ACADIA will discuss today&#146;s announcement from its Phase 3 trial of pimavanserin for the treatment of patients with
dementia-related psychosis via conference call and webcast today at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">855-638-4820</FONT></FONT> for participants
in the U.S. or Canada and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">443-877-4067</FONT></FONT> for international callers (reference passcode 9785159). A telephone replay of the conference call may be accessed through
September&nbsp;16, 2019 by dialing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">855-859-2056</FONT></FONT> for callers in the U.S. or Canada and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">404-537-3406</FONT></FONT> for international callers (reference passcode 9785159). The conference call will also be webcast live on ACADIA&#146;s website, www.acadia-pharm.com, in the
investors section and will be archived there until October&nbsp;9, 2019. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>About Dementia-Related Psychosis </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Around 8&nbsp;million people in the United States are living with dementia and studies suggest that approximately 30% of dementia patients, or
2.4&nbsp;million people, have psychosis, commonly consisting of delusions and hallucinations<SUP STYLE="font-size:85%; vertical-align:top">1,2</SUP>. Dementia-related psychosis includes psychosis in Alzheimer&#146;s disease, dementia with Lewy
bodies, Parkinson&#146;s disease dementia, vascular dementia, and frontotemporal dementia. Serious consequences have been associated with severe or persistent psychosis in patients with dementia such as repeated hospital admissions, increased
likelihood of nursing home placement, progression of dementia, and increased risk of morbidity and mortality<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>About Pimavanserin </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting <FONT STYLE="white-space:nowrap">5-HT</FONT><SUB
STYLE="font-size:85%; vertical-align:bottom">2A</SUB> receptors. These receptors are thought to play an important role in psychosis, schizophrenia, depression and other neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable
binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. ACADIA is evaluating pimavanserin in an extensive clinical development program across multiple indications with significant unmet need including
dementia-related psychosis, adjunctive major depressive disorder, and the negative symptoms of schizophrenia. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson&#146;s disease psychosis by the U.S.
Food and Drug Administration in April 2016 under the trade name NUPLAZID<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. NUPLAZID is not approved for dementia-related psychosis, schizophrenia or major depressive disorder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>About ACADIA Pharmaceuticals </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson&#146;s disease psychosis. ACADIA also has ongoing clinical
development efforts in additional areas with significant unmet need, including dementia-related psychosis, major depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome. This press release and further information about ACADIA
can be found at: www.acadia-pharm.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>Forward-Looking Statements </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are
not limited to, statements related to: intended activities with respect to the HARMONY study following the interim analysis, expected timelines with respect to full data from the HARMONY study and the Company&#146;s planned engagement with the FDA.
These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other
factors, please refer to ACADIA&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018 as well as ACADIA&#146;s subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking statements, which speak </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><U>Important Safety Information and Indication for NUPLAZID (pimavanserin) </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>&#149;</B></P></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk
of death. </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>&#149;</B></P></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the
hallucinations and delusions associated with Parkinson&#146;s disease psychosis. </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>Contraindication</B>: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction
to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>QT Interval Prolongation</B>: NUPLAZID prolongs the QT interval. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></P></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other
drugs known to prolong QT interval including Class&nbsp;1A antiarrhythmics or Class&nbsp;3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></P></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other
circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>Adverse Reactions</B>: The most common adverse reactions (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>2%
for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs &lt;1%). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>Drug Interactions</B>: </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></P></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce
NUPLAZID dose to 10 mg taken orally as one tablet once daily. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></P></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of
strong or moderate CYP3A4 inducers with NUPLAZID. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>Indication</B>: NUPLAZID is indicated for the treatment of
hallucinations and delusions associated with Parkinson&#146;s disease psychosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>Dosage and Administration</B>: Recommended dose: 34
mg capsule taken orally once daily, without titration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">NUPLAZID is available as 34 mg capsules and 10 mg tablets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Please see the full <U><FONT STYLE="font-family:Times New Roman" COLOR="#2a3749">Prescribing Information</FONT></U><FONT
STYLE="font-family:Times New Roman"> including <B>Boxed WARNING</B> for NUPLAZID. </FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>References </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP> 2017 Alzheimer&#146;s Disease Facts and Figures and ACADIA market research </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>Plassman BL, et al. Prevalence of dementia in the United States: the Aging Demographics,
and Memory study. <I>Neuroepidemiology</I>. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2007;29(1-2):125-132.</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>Connors MH et al. <I>Am J Geriatr Psychiatry</I> 2018;26(3). Peters ME et al. <I>Am J
Psychiatry</I> 2015;172(5). Haupt M et al. <I>Int J Geriatr Psychiatry </I>1996;11(11). Naimark D et al. <I>J Am Geriatr Soc</I> 1996;44(3). Stern Y et al. <I>Neurology</I> 1994;44(12). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>Investor Contact: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">ACADIA
Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Mark Johnson, CFA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(858) <FONT STYLE="white-space:nowrap">261-2771</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">ir@acadia-pharm.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>Media
Contact: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">ACADIA Pharmaceuticals Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Maurissa Messier </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(858) <FONT
STYLE="white-space:nowrap">768-6068</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">media@acadia-pharm.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>acad-20190909.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.2 - Release 2019.2 -->
<!-- Creation date: 9/9/2019 11:56:03 AM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:acad="http://www.acadia-pharm.com/20190909"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.acadia-pharm.com/20190909"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20190909_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20190909_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>acad-20190909_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.2 - Release 2019.2 -->
<!-- Creation date: 9/9/2019 11:56:03 AM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>acad-20190909_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.2 - Release 2019.2 -->
<!-- Creation date: 9/9/2019 11:56:04 AM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acad-20190909.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g800506g0909073947301.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g800506g0909073947301.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P *4# 2(  A$! Q$!_\0
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M=U:3++!)G:Z]\'!_$$$45F>$IM2N/#%G+J\ AOFW>8 FS=\QPY7L6&&(]Z*
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d800506d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acad-20190909.xsd" xlink:type="simple"/>
    <context id="duration_2019-09-09_to_2019-09-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070494</identifier>
        </entity>
        <period>
            <startDate>2019-09-09</startDate>
            <endDate>2019-09-09</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2019-09-09_to_2019-09-09"
      id="Hidden_dei_EntityRegistrantName">ACADIA PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2019-09-09_to_2019-09-09">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2019-09-09_to_2019-09-09"
      id="Hidden_dei_EntityCentralIndexKey">0001070494</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2019-09-09_to_2019-09-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2019-09-09_to_2019-09-09">2019-09-09</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2019-09-09_to_2019-09-09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2019-09-09_to_2019-09-09">000-50768</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2019-09-09_to_2019-09-09">06-1376651</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2019-09-09_to_2019-09-09">3611 Valley Centre Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2019-09-09_to_2019-09-09">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2019-09-09_to_2019-09-09">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2019-09-09_to_2019-09-09">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2019-09-09_to_2019-09-09">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2019-09-09_to_2019-09-09">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2019-09-09_to_2019-09-09">558-2871</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2019-09-09_to_2019-09-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2019-09-09_to_2019-09-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2019-09-09_to_2019-09-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2019-09-09_to_2019-09-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2019-09-09_to_2019-09-09">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2019-09-09_to_2019-09-09">ACAD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2019-09-09_to_2019-09-09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2019-09-09_to_2019-09-09">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MP^\B['OK=NX?&Y\%=0.__H7^ E!+ P04    " #$-2E/F5R<(Q &  "<)P
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M5GTSVD^,[(9&.QN[_?4_4$L#!!0    ( ,0U*4_>!%RJ:@(  $X&   4
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M#?Y?S@;#0I32.-TM!%2EIAV:L;IE//S5AIP(V).T0'AKWY;K 7)-+1,BC,1
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M;SP@,,XA5!LOXI%TIK=WDWL.N]?Z@;%W^^I4TH\:X\<M?P!02P,$%     @
MQ#4I3__ )@B]    A0(  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<ZV200J#,!  OR)Y0%=MZ:&HIUZ\MOU T-6(FH3LENKOFWI10:$'+PEAP\Q
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M"=MA/7;AWR"I83KOUO]H=)G+H%W\S<A'2NU!7PW_R?(+4$L! A0#%     @
MQ#4I3Q\CSP/     $P(   L              ( !     %]R96QS+RYR96QS
M4$L! A0#%     @ Q#4I3R?HAPZ"    L0   !               ( !Z0
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #$-2E/*9!//.X    K @
M$0              @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #$-2E/F5R<(Q &  "<)P  $P              @ &V @  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,0U*4]@S,*=J0(  /D+   8
M      "  ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #$-2E/W@1<JFH"  !.!@  %               @ '6"P  >&PO<VAA<F5D
M4W1R:6YG<RYX;6Q02P$"% ,4    " #$-2E/NJ$YBM<!   R!@  #0
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4!08     "@ * ( "   K%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>12
<FILENAME>0001193125-19-240440-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-19-240440-xbrl.zip
M4$L#!!0    ( ,0U*4\-F $ 8P,  #(,   1    86-A9"TR,#$Y,#DP.2YX
M<V2]5M]/&SD0?J_4_V&Z3W?2[3H;!&U6A H=14(">DKAU#?D>)W$JM?>L[U
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MT(;A!<*Z7HHG;M21_A4PV2F:_B(4=>9_4$L#!!0    ( ,0U*4\M3AFKS00
M -<L   5    86-A9"TR,#$Y,#DP.5]P<F4N>&ULW9KO;^(V&,??GW3_@Y=[
MLTE+0J#M#E1Z0K0]H?67@-NFO3F9Y &L.79DFP+__>P0WQ$('?1V4[PB 77\
M??SU\W&<V.3RPRJEZ!F$))QUO2AH> A8S!/"9EUO(7TL8T(\)!5F"::<0==;
M@_0^7+U]<_F#[Z/KV\$#\M%<J4QVPG"Y7 ;)E##)Z4+ID#*(>1HBW[?U^^-/
MZ+=-<QW42W0[Z*(97 3O@Z8.,P0*6 )J-J*V*?@J$X!-/)1@!1W4#MNAJ8.B
MJ'-^T6F<H=X]NL%2@6!H3%+8EO)L+<ALKM"/\4]Y9'3-&0-*88UN"<,L)IBB
MD77\,QJP.$ ]2M'0R*1V)4$\0Q(442EA?W7,V\1X16_?(/VG\\AD7MKU3#:*
M9*PF@@9<S+3=1BNT(F];L]H3+5NY)&JWVV%^M%Q?DJK:NH$H_./^;A3/(<6^
M9J"9Q3M-:3>)^J+>-G<>;@[:^I)T9![ICL=YZH_H%CI8P_SGVVJ^*?*CIM^*
M@I5,O"O3Y":K@E,8PA29ST_#0:E-'..$8#^;8Y'FPRH? @W]"A5><<;3=6AT
MX36/%RDP93][++EABJCU@$VY2//>>"A/;&<N8-KU3&C?1C.>W@UUH,^G!%+K
M3)\;DJ09!0^%6WW*A!X_3.6U[W1!20 K!2R!Q(8Q'?B.O;[:T"V&,(]+6; G
M<8Y.0AS,^'.8 ,E;-%_R%/F-J #W3A=][G,]>_0F4@D<JW(RJ!DY7-A"BB=
MNUZ%*/SW;6VZ/H09,8TP]8!3.-9=M;9L<AMJ3\2ER%C$-JK^ND>T?&84-<(,
M"QW/C^>$?AD,4\'3RH05K?&7_'*1@.AZS6:@)P8/98)PH:OI$@\MI+;$,V,>
M4W,,IB $)'>;)!PTFSO5DZR$O.9W(=?3@S<Q _B6XMFQR'9$]66U8]1":CD&
M:3/D^KH? M.!GL!6O\+ZM/-K3UQ?: <,6WAGCL&S5XBQ3N:QS,J:^J(J^[2$
M+APE] 3:L;Z,)]?ZMO=45#OB^C/;,6SA_>(8/'O7%7.1<9%G>*03#7V^T!/(
MNL^3$^]$_B%4?<$>9=]B?N\DYEM"X6&13D"<QG1;5W> VUXMK;:3M,9X-4AT
M,LB4;!:UKT%W,$C=.1XT7D!M-9R$VDL2G6I9?.@5-D2G :T,4'>8E:8MR.A_
M K+YK2";+H)L?@7IVN*]U*6^_OHHQGS)7H5Q6^X(Q&W+%J&;2_NB0_GMVJ-X
M$OR9F,WDUW#<B^$(S#W?EJAKZ_U2KYZX5)C^2;+3UR'5$1RAN>/:LCQWC*69
M87H"\"GTRIKZ\BK[M(1<V[LQOY?1ISEG)ZX+]W7U);7OU=)R;;/F=^U2 >OS
M-%VP8EDDCT5V0%Q?;@<,6WBN;<&,."4Q483-[O6E6A!C\#AR5<KZ8JMR:YFY
MMA'S), ,/]!W5/D^O?GU6SQ.I\=/E"]%J"_#EUP7+,]<VW_9Z=- R@6(;R=:
M$<<9KA7>+5W7-F5&$"^,T:@Y&1-%C[[=W-?5E]Z^5TO+M9V7L<#FH;W1.IWP
MHR^#.Z+Z<MHQ:B&YMK=BA]O-*IYC-H-3GDJJUM876;5?2\[-/92;%,1,C\./
M@B_57,_[&68G/O9R($1].;YHV^+\#[91+L.]U-SI O- [N:(>3./E^J2OP%0
M2P,$%     @ Q#4I3SUAM:K/%   Q7X   X   !D.# P-3 V9#AK+FAT;>T]
M:5/C.-K?WZK]#ZKT.[-016Z@(=!L90/=0W4W4,#LSNZ7*<56B ;'\DARCOGU
M^SR2[-B)$Q+N[F8.P+&.Y[YTY/ ?XT% ADPJ+L(/I7JE5B(L](3/PYL/I5CW
MRGLE\H^CO_W?85]#0V@<JI;/^(=27^NH5:V.NS*H*.95;L2P"B^JC5I]OURK
MEYOUDFL>J[*>1$RE?7I4=2M"WE23-P6=0A&&\2#M,AJ-*F8J[.9K6<5^56A4
MAE9,<B_I-PYX>)OK-FJ:3O7]_?VJ>9LTG6N93M"HU9I5?-VEBB7-J4?]7'/\
M@--RU*=R4/'$P&!1@W]36!0O@@1&KU=_^_KERNNS 2WS4&D:>ND\L98+H=JO
MPMND(5=BNU%_OP0%UR+M,%[4M@YM0T"8_?;/RR_3YKJX_;1I54L:JIZ0 ZI!
M@'"DG7*M46[L9@8I@WCD!DK$Y:YQ]C+RH+A7+'/P IO7\^*#3?@RRLP0'=_Z
M,U+M&N]6[4O7=+%LH8:4C*HPZN-OS77 CO;*GP^K]D_X;, T)3A"F?T9\^&'
M4D>$FH6Z? T"72*>??I0TFRLJV9$4L5^53<H(>2P*_P)_GGH\R%1>A*P#R6?
MJRB@$]0;5CHBAWS<PAY,NK^Y[[/0_@U-SJS2$ X2_8MY]3OH[N\G(< YN60W
M7"%#]!D= $PA_(0)&&\5OS<PC_4EZT&K6!H._FXU&O_[78O,4^FHW6D?G[;)
MQ2_MRZ_MSLFOUZ>=]I<K<GK6.:SFH)N#=@I(>\!"'_[7'P-ZLS8$/1HH=M=D
MA:3IP)22!J>AS\:?V62>-G,-U@2M!K:A]KZVO;\]#U]UAH^2]9@$8\T4/*.U
M:BEC46 N8@Q="XWDAY+B@RA 23>?]26"@K:KG-BKRECYR6LJ/2E0H%:VBT]@
M<8\.JWE\'/8YC,VS$K&TCT;C6X[<AGLKD#OIQ@SSTD?NXP<]SB0Q(+!"\]4Y
M_9QGV&QGA+IP_ @X*OST$4R1U,=4LZ,I;$G/Z;LIK/Z"MLF;=-ITGFJ..BDU
MI]2K9NU%%>S*4<ZZ]*!C6?&_6*M>B_3!B/NZW]JK[/#P8$#E#0];-4)C+4KY
M;CA9F0;\)FQY0 (F\7V4O$7C7^XS?M/7K5IE!\;M"@D0E+M":S' SVK1F"@1
M<)^\JYE_W-3U6NTG-W-9BZB%0+G'I'.D2T<_OZOOU@X.J]%1 4ZK ]=\7- :
MQ:"E4\\B,LX.MXV=L5NF@^%.CPYX,&E=\P%3Y(R-R*48T/# O!M9/+HB\ _F
MT#[(,'>OB(XSV)2.?CT[O3XY)E?7[>N3JQ>&Y>JD\^OEZ?7IR15IGQV3D]\Z
MO[3//IV0SOG7KZ=75Z?G9T\&8&,E /_=OOKE].S3]?G9%CFN="JD4=O9WK=
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M?IGJL&J^ _O0?$/VT?\ 4$L#!!0    ( ,0U*4^;XZTU^Q<  *!L   1
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MI\RN$\U;!P/-!506Q@APIC15?<S*5(Z"6IYUVR29&8OPJS(%L,7%?H^#UO,
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M@$HFR)/EZBYI+NM)J%@_*=WU\"9];]+W_TWZ^)8&5]%)EJDDDC!%L;GV9+[
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MA;=A;F_M5+?J6SM%]GW!>5(!@IS/P/.-7AC*%^U;/.2_F>P_4$L! A0#%
M  @ Q#4I3PV8 0!C P  ,@P  !$              ( !     &%C860M,C Q
M.3 Y,#DN>'-D4$L! A0#%     @ Q#4I3QPOMV2%!@  24<  !4
M     ( !D@,  &%C860M,C Q.3 Y,#E?;&%B+GAM;%!+ 0(4 Q0    ( ,0U
M*4\M3AFKS00  -<L   5              "  4H*  !A8V%D+3(P,3DP.3 Y
M7W!R92YX;6Q02P$"% ,4    " #$-2E//6&UJL\4  #%?@  #@
M    @ %*#P  9#@P,#4P-F0X:RYH=&U02P$"% ,4    " #$-2E/F^.M-?L7
M  "@;   $0              @ %%)   9#@P,#4P-F1E>#DY,2YH=&U02P4&
2      4 !0!  0  ;SP

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6627273056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 09, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACADIA PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  09,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1376651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3611 Valley Centre Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">558-2871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACAD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d800506d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d800506d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acad-20190909_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acad-20190909_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "acad-20190909.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "acad",
   "nsuri": "http://www.acadia-pharm.com/20190909",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d800506d8k.htm",
      "contextRef": "duration_2019-09-09_to_2019-09-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d800506d8k.htm",
      "contextRef": "duration_2019-09-09_to_2019-09-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d800506d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acadia-pharm.com//20190909/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d800506d8k.htm">d800506d8k.htm</File>
    <File>acad-20190909.xsd</File>
    <File>acad-20190909_lab.xml</File>
    <File>acad-20190909_pre.xml</File>
    <File>d800506dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
